An interventional study of Narrowband UVB phototherapy in Psoriasis, sponsored by Psoriasis Treatment Center of Central New Jersey. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-01-30.
Sponsored by Psoriasis Treatment Center of Central New Jersey · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Psoriasis by Psoriasis Treatment Center of Central New Jersey — 5 open to participants now, 5 under way, none of them phase 3. Psoriasis · Psoriasis Treatment Center of Central New Jersey.
Among the 13 studies in Psoriasis by Psoriasis Treatment Center of Central New Jersey, this one is the 2nd largest by planned enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2017, is the only one with no phase, and was the 5th registered.
2,032 studies on the registry are indexed under Psoriasis; 278 are open to participants now.
Browse Psoriasis studies →5 of the 13 studies in Psoriasis by Psoriasis Treatment Center of Central New Jersey are open now, in 1 country. Recruiting first, the newest first:
Psoriasis Treatment Center of Central New Jersey · Sites in United States
Ages 18+
Psoriasis Treatment Center of Central New Jersey · Sites in United States
Ages 18+
Psoriasis Treatment Center of Central New Jersey · Sites in United States
Ages 18+
Psoriasis Treatment Center of Central New Jersey · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 175 Psoriasis studies recruiting now, 92 (53%) set no upper age limit and 67 (38%) stop at 75 or younger; 25 take children under 18; 42 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2015; this study’s year is marked. 2 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 75 across 1,568 interventional studies indexed under Psoriasis.
Median enrollment 27 across the 12 interventional studies, 3 across the 1 observational. Of the 8 that completed or were terminated, 4 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
Psoriasis Treatment Center of Central New Jersey is the lead sponsor of 17 studies on the registry; 6 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 1 (20%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 13 studies in Psoriasis by Psoriasis Treatment Center of Central New Jersey, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A single center study of 30 patient receiving Narrowband UVB phototherapy three times weekly for 12 weeks. Patients will be evaluated through week 36 to evaluate maintenance of response.
30 subjects will be treated with increasing doses of Narrowband Ultraviolet phototherapy three times weekly for 12 weeks. Patients will then be evaluated every 6 weeks through week 36 to determine maintenance of response.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Open Label Narrowband UVB phototherapy for 12 weeks.
Device: Narrowband UVB phototherapy
Ultraviolet B phototherapy
Psoriasis area severity index score
PASI 75
Time frame: 12 weeks
Physicians Global Assessment
PGA improvement
Time frame: 12 weeks
Body Surface Area
BSA improvement
Time frame: 12 weeks
Physician's Global Assessments multiplied by Body surface area
PGA x BSA
Time frame: 12 weeks
Plan to share: No
No publications or documents are linked to this record.
Started Nov 2017 (actual). Primary completion is estimated for Dec 2019, 24 months after the start.
Of 115 non-industry interventional studies with no phase under Psoriasis, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 24 months is above that.
Counting every sponsor, half of 134 studies reached it within 19 months; a quarter within 8 and three quarters within 38.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Psoriasis Treatment Center of Central New Jersey